sentis™
Cancer + Discovery Panel

"Gain insight into clinically actionable mutations and discover new treatment targets with one of the market's most comprehensive and affordable panels"

SENTIS™ Cancer + Discovery Panel (Tissue/ctDNA)

Introduction

Technological advances combined with an improved understanding of the genetic basis of cancer has revolutionized the way we manage cancer. Utilizing the patient's particular genomic profile, clinicians can now assess the risk of hereditary cancer for the patient and the patient's family, also tailor the best treatment options.

SENTIS™ Cancer + Discovery provides clinicians with one of the market's most comprehensive and accurate Next Generation Sequencing (NGS) based testing solution for the identification of clinically actionable mutations and the discovery of novel variants with important functions in cancer. Supporting both tissue sample and liquid biopsy, the panel offers **816 cancer-related genes and interrogates the most common types of alterations,** including **SNVs, indels, CNVs, and fusions in solid tumors.**

Sample Requirements

SENTIS™ Cancer + Discovery (Tissue)

- >60mg tissue or 15 FFPE 10mm*10mm (5-10μm) sections or ≥3 samplings of biopsy or ≥3μg good quality, tumor DNA
- 5mL of peripheral blood

SENTIS™ Cancer + Discovery (ctDNA)

- 2 tubes of ≥ 8mL peripheral venous blood (≥ 4mL plasma) using Streck Cell-Free DNA BCT® tube

TAT

- 12 working days (from receipt of the sample to report issuance)

Liquid biopsy version allows genetic profiling in situations where tissue is not available or continuous monitoring of tumor molecular profile is required.

Gene Panel Overview



Workflow

1. Counselling and Consent
2. Sample Collection
3. DNA Extraction and QC
4. Targeted Capture and NGS
5. Data Analysis and Interpretation
6. Report Ready
7. Genetic Counselling

Advantages

Comprehensive

- Covering 816 cancer-related genes, supporting most common types of genomic alterations including SNV, InDel, CNV, fusion, TMB and MSI
- Includes genes associated with both sporadic and hereditary cancers
- Provides interpretation on the therapeutic relevance in 360+ drugs, including 360+ targeted therapies (both approved and currently in clinical trials), 11+ immunotherapies and 11+ commonly used chemotherapies
- Includes 425+ genes in cancer-related pathways for discovery of novel pathogenic variants

Flexible

- SENTIS™ Cancer + Discovery (Tissue): Fresh tumor tissue; FFPE slices; DNA; Peripheral blood (Control)
- SENTIS™ Cancer + Discovery (ctDNA): Plasma; Peripheral blood

Reliable

- The median adequate sequencing depth is up to 1200x using tissue samples and up to 2700x using ctDNA

www.bgi.com/global/
info@bgi.com

Published in Aug 2024.

@BGI Genomics